This Article Full Text Full Text (PDF) All Versions of this Article: 34/5/1246    most recent 01.STR.0000068170.80517.B3v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aronowski, J. Articles by Grotta, J. C. Search for Related Content PubMed PubMed Citation Articles by Aronowski, J. Articles by Grotta, J. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAFFEINE ETHANOL Related Collections Animal models of human disease Ischemic biology - basic studies Acute Cerebral Infarction Neuroprotectors

(Stroke. 2003;34:1246.)
© 2003 American Heart Association, Inc.

Original Contributions

Ethanol Plus Caffeine (Caffeinol) for Treatment of Ischemic Stroke

Preclinical Experience

From the Stroke Program, Department of Neurology, University of Texas at Houston Medical School, Houston, Tex.

Reprint requests to Dr Jaroslaw Aronowski, Department of Neurology, University of Texas at Houston Medical School, 6431 Fannin, Room 7.044, Houston, TX 77030. E-mail J.Aronowski{at}uth.tmc.edu

Background and Purpose— Ethanol and caffeine are 2 common psychoactive dietary components. We have recently shown that low-dose ethanol plus caffeine results in a 70% to 80% reduction of infarct volume after reversible common carotid/middle cerebral artery (CCA/MCA) occlusion in rats. The combination (caffeinol) was effective after either oral pretreatment or intravenous administration starting up to 2 hours after stroke onset. Ethanol alone aggravated ischemic damage, while caffeine alone was without effect. Daily caffeinol for 2 weeks before ischemia eliminated the neuroprotection seen with acute treatment (tolerance). The purpose of our present study was to further characterize the properties of caffeinol as a possible treatment for ischemic stroke.

Methods— The transient CCA/MCA occlusion model was used in all experiments. Five sets of experiments were conducted (1) to test the effectiveness of various doses of ethanol (0.2 to 0.65 g/kg) and caffeine (3 to 10 mg/kg) in the caffeinol mixture; (2) to test whether the neuroprotective dose of caffeinol can improve behavioral dysfunction; (3) to test whether chronic ethanol or caffeine before ischemia will affect efficacy of caffeinol treatment; (4) to test whether the protective effect of caffeinol can be improved by pairing it with 35°C hypothermia; and (5) to test whether caffeinol affects frequency of hemorrhage after administration of recombinant tissue plasminogen activator (rtPA) in ischemic animals.

Results— Doses as low as 0.2 g/kg of ethanol and 6 mg/kg of caffeine in the caffeinol were effective in reducing cortical infarct volume and behavioral dysfunction after transient CCA/MCA occlusion. Daily exposure to ethanol but not caffeine before CCA/MCA occlusion eliminated the therapeutic efficacy of acute caffeinol treatment, similar to the tolerance observed after chronic exposure to caffeinol. The therapeutic effect of caffeinol could be further improved by pairing it with mild intraischemic hypothermia, and caffeinol did not increase hemorrhagic infarction when given in combination with rtPA.

Conclusions— Low doses of caffeinol, equivalent to no more than 2 to 3 cups of strong coffee and 1 cocktail, are consistently and highly neuroprotective, are well tolerated, can be added to other therapies to increase the effect of each, and do not interfere with or complicate rtPA therapy. Caffeinol is an appropriate candidate for clinical trial in stroke patients, although it may be less effective in patients with regular alcohol intake.

Key Words: caffeine • cerebral ischemia, focal • ethanol • intracerebral hemorrhage • neuroprotection

This article has been cited by other articles:

				B. P. Meloni, F. L. Mastaglia, and N. W. Knuckey Review: Therapeutic applications of hypothermia in cerebral ischaemia Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 75 - 98. [Abstract] [PDF]

				M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]

				X. Zhao, S.-J. Liu, J. Zhang, R. Strong, J. Aronowski, and J. C. Grotta Combining Insulin-Like Growth Factor Derivatives Plus Caffeinol Produces Robust Neuroprotection After Stroke in Rats Stroke, January 1, 2005; 36(1): 129 - 134. [Abstract] [Full Text] [PDF]

				R. R. Ratan, A. Siddiq, L. Aminova, P. S. Lange, B. Langley, I. Ayoub, J. Gensert, and J. Chavez Translation of Ischemic Preconditioning to the Patient: Prolyl Hydroxylase Inhibition and Hypoxia Inducible Factor-1 as Novel Targets for Stroke Therapy Stroke, November 1, 2004; 35(11_suppl_1): 2687 - 2689. [Abstract] [Full Text] [PDF]

				M. A. Schwarzschild, K. Xu, E. Oztas, J. P. Petzer, K. Castagnoli, N. Castagnoli Jr., and J.-F. Chen Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease Neurology, December 9, 2003; 61(90116): S55 - 61. [Abstract] [Full Text]

				P. Piriyawat, L. A. Labiche, W. S. Burgin, J. A. Aronowski, and J. C. Grotta Pilot Dose-Escalation Study of Caffeine Plus Ethanol (Caffeinol) in Acute Ischemic Stroke Stroke, May 1, 2003; 34(5): 1242 - 1245. [Abstract] [Full Text] [PDF]